Lindsley F Kimball Research Institute, New York Blood Center, New York, NY, USA.
Expert Rev Vaccines. 2012 Dec;11(12):1405-13. doi: 10.1586/erv.12.126.
A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.
一种亚单位疫苗 RBD-S 正在开发中，用于预防由严重急性呼吸系统综合征冠状病毒（SARS-CoV）引起的严重急性呼吸系统综合征（SARS），该病毒被美国国立卫生研究院（NIH）归类为 C 类病原体。该疫苗由重组 SARS-CoV 刺突（S）蛋白的受体结合域（RBD）和铝佐剂组成，同时还含有合成的葡糖基脂质 A。该疫苗可诱导中和抗体而不引起 Th2 型免疫病理学。非营利性产品开发伙伴关系；Sabin 疫苗研究所和德克萨斯儿童医院疫苗开发中心正在与两个学术合作伙伴（纽约血液中心和德克萨斯大学医学分校）；一个工业合作伙伴（免疫设计公司）；和沃尔特·里德陆军研究所。概述了 RBD-SARS 疫苗产品开发的路线图，目标是在未来 5 年内制造该疫苗进行临床测试。
